Transino has 240 milligram of L- cysteine

and contains 1000 milligram of Vitamin C

Transino® was especially successful. Based on

tranexamic acid, it went on sale in September 2007 as the

first medication approved in Japan as effective against

skin discoloration caused by melasma. Sales reached

¥2.6 billion over the next six months

Melasma is a condition that causes skin blemishes in areas around the

cheekbones and commonly occurs in women in their thirties and forties. The

blemishes tend to be symmetrically distributed in terms of size and shape on

the left and right sides of the face. Regarded as diffi cult to cure, the condition

can also appear on the forehead and around the mouth. The results of a survey

of 1,000 people conducted by DSHC in 2006 showed that melasma was

the suspected cause in one in three cases of skin blemishes affecting women

within a one-year period. The onset of melasma is believed to be linked in some way

to hormonal conditions in women. Stress is also thought to be involved. Laser treatment

reportedly causes the condition to worsen.

Treatment with tranexamic acid, which is the main ingredient of Transino®, is

effective against melasma. Transino® is the only OTC drug approved in Japan as

being effective against skin blemishes caused by melasma. Further information on

melasma and Transino® can be found on the websites to the right (information only

available in Japanese)

What is Melasma?

How to Use:

• 6 tablets a day (2 tablets after each meal --> breakfast, lunch and dinner with warm water)

• Daily dose (6 tablets)
  • Tranexamic acid 750mg
  • L-Cysteine 240mg
  • 300mg Ascorbic acid (vitamin C) 300mg
  • Pyridoxine hydrochloride (vitamin B6) 6mg
  • Calcium pantothenate 24mg